{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:26:44Z","timestamp":1772119604904,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Division of Hematology-Oncology, Upstate Cancer Center, of the Upstate Medical University."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s10549-025-07868-3","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:24:05Z","timestamp":1765196645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of adjuvant chemotherapy on overall survival in premenopausal (age\u2009\u2264\u200950\u00a0years) hormone and node positive breast cancer patients with an Oncotype Dx score of 25 or less. A NCDB analysis"],"prefix":"10.1007","volume":"215","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6236-2822","authenticated-orcid":false,"given":"Prashanth","family":"Ashok Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghanshyam","family":"Ghelani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gowthami","family":"Koorapati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shweta","family":"Paulraj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danning","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abirami","family":"Sivapiragasam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"7868_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9238084","volume":"2020","author":"HI Assi","year":"2020","unstructured":"Assi HI, Alameh IA, Khoury J, Abdul Halim N, El Karak F, Farhat F et al (2020) Impact of commercialized genomic tests on adjuvant treatment decisions in early stage breast cancer patients. J Oncol 2020:9238084","journal-title":"J Oncol"},{"issue":"25","key":"7868_CR2","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","volume":"385","author":"K Kalinsky","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al (2021) 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med 385(25):2336\u20132347","journal-title":"N Engl J Med"},{"issue":"2","key":"7868_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"4","key":"7868_CR4","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","volume":"22","author":"M Piccart","year":"2021","unstructured":"Piccart M, van \u2019t Veer LJ, Poncet C, Lopes Cardozo JMN, Delaloge S, Pierga JY et al (2021) 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol 22(4):476\u2013488","journal-title":"Lancet Oncol"},{"issue":"3","key":"7868_CR5","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s10549-020-05971-1","volume":"185","author":"R Weiser","year":"2021","unstructured":"Weiser R, Haque W, Polychronopoulou E, Hatch SS, Kuo YF, Gradishar WJ et al (2021) The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis. Breast Cancer Res Treat 185(3):667\u2013676","journal-title":"Breast Cancer Res Treat"},{"key":"7868_CR6","unstructured":"survival rates for breast cancer | American Cancer Society [Internet][cited 2024 Jul 15] [Available from: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/understanding-a-breast-cancer-diagnosis\/breast-cancer-survival-rates.html."},{"key":"7868_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00390","volume":"8","author":"P Ashok Kumar","year":"2024","unstructured":"Ashok Kumar P, Wang D, Huang D, Sivapiragasam A (2024) Adjuvant chemotherapy in premenopausal patients with hormone-positive breast cancer with a recurrence score of 16-25: a retrospective analysis using the National Cancer Database. JCO Precis Oncol 8:e2300390","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"7868_CR8","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1245\/s10434-024-15393-8","volume":"31","author":"BE Palis","year":"2024","unstructured":"Palis BE, Janczewski LM, Browner AE, Cotler J, Nogueira L, Richardson LC et al (2024) The National Cancer Database conforms to the standardized framework for registry and data quality. Ann Surg Oncol 31(9):5546\u20135559","journal-title":"Ann Surg Oncol"},{"key":"7868_CR9","unstructured":"Site Recode ICD-O-3\/WHO 2008 SEER Data reporting tools 2024 [cited 2024 7\/21\/2025]. Available from: https:\/\/seer.cancer.gov\/siterecode\/icdo3_dwhoheme\/index.html."},{"issue":"3","key":"7868_CR10","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamaoncol.2020.7320","volume":"7","author":"KF Hoskins","year":"2021","unstructured":"Hoskins KF, Danciu OC, Ko NY, Calip GS (2021) Association of race\/ethnicity and the 21-gene recurrence score with breast cancer-specific mortality among US women. JAMA Oncol 7(3):370\u2013378","journal-title":"JAMA Oncol"},{"issue":"10","key":"7868_CR11","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","volume":"14","author":"M Kwa","year":"2017","unstructured":"Kwa M, Makris A, Esteva FJ (2017) Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol 14(10):595\u2013610","journal-title":"Nat Rev Clin Oncol"},{"key":"7868_CR12","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw197","author":"C Schmidt","year":"2016","unstructured":"Schmidt C (2016) Mammaprint reveals who can skip chemotherapy for breast cancer. J Natl Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djw197","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"7868_CR13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.whi.2018.08.001","volume":"28","author":"SF Gallups","year":"2018","unstructured":"Gallups SF, Connolly MC, Bender CM, Rosenzweig MQ (2018) Predictors of adherence and treatment delays among African American women recommended to receive breast cancer chemotherapy. Womens Health Issues 28(6):553\u2013558","journal-title":"Womens Health Issues"},{"issue":"2","key":"7868_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s10549-018-4909-5","volume":"172","author":"AK Green","year":"2018","unstructured":"Green AK, Aviki EM, Matsoukas K, Patil S, Korenstein D, Blinder V (2018) Racial disparities in chemotherapy administration for early-stage breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat 172(2):247\u2013263","journal-title":"Breast Cancer Res Treat"},{"key":"7868_CR15","doi-asserted-by":"publisher","first-page":"1115208","DOI":"10.3389\/fonc.2023.1115208","volume":"13","author":"N Stabellini","year":"2023","unstructured":"Stabellini N, Cao L, Towe CW, Luo X, Amin AL, Montero AJ (2023) Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in ER+\/HER2- breast cancer pts with 1\u20133 positive nodes and oncotype DX recurrence score 20 to 25: an NCDB analysis. Front Oncol 13:1115208","journal-title":"Front Oncol"},{"issue":"2","key":"7868_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10549-017-4162-3","volume":"163","author":"MC Roberts","year":"2017","unstructured":"Roberts MC, Miller DP, Shak S, Petkov VI (2017) Breast cancer-specific survival in patients with lymph node-positive hormone receptor-positive invasive breast cancer and Oncotype DX Recurrence Score results in the SEER database. Breast Cancer Res Treat 163(2):303\u2013310","journal-title":"Breast Cancer Res Treat"},{"issue":"22","key":"7868_CR17","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1056\/NEJMoa0909638","volume":"362","author":"SM Swain","year":"2010","unstructured":"Swain SM, Jeong JH, Geyer CE Jr, Costantino JP, Pajon ER, Fehrenbacher L et al (2010) Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 362(22):2053\u20132065","journal-title":"N Engl J Med"},{"issue":"2","key":"7868_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, L\u00e1ng I et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122\u2013137","journal-title":"N Engl J Med"},{"issue":"7","key":"7868_CR19","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.22.01064","volume":"41","author":"O Pagani","year":"2023","unstructured":"Pagani O, Walley BA, Fleming GF, Colleoni M, L\u00e1ng I, Gomez HL et al (2023) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials. J Clin Oncol 41(7):1376\u20131382","journal-title":"J Clin Oncol"},{"key":"7868_CR20","unstructured":"A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive\/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 (OFSET) [Internet]. 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05879926."}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-025-07868-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-025-07868-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T12:38:50Z","timestamp":1767789530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-025-07868-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["7868"],"URL":"https:\/\/doi.org\/10.1007\/s10549-025-07868-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7201172\/v1","asserted-by":"object"}]},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors. The SUNY Upstate IRB has reviewed the project and has determined this project does not meet the definition of human subject research under the purview of the IRB according to federal regulations. IRB no: 1778292.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable. Data were obtained from the NCDB PUF file. It is a Health Insurance Portability and Accountability Act (HIPAA) complaint data file where patient information is de-identified.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"32"}}